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Abstract
Background: This study examined whether MS patients and proxy respondents agreed on change
in disease impact, which was induced by treatment. This may be of interest in situations when
patients suffer from limitations that interfere with reliable self-assessment, such as cognitive
impairment.
Methods: MS patients and proxies completed the Multiple Sclerosis Impact Scale (MSIS-29) before
and after intravenous steroid treatment. Analyses focused on patient-proxy agreement between
MSIS-29 change scores. Transition ratings were used to measure the patient's judgement of change
and whether this change was reflected in the MSIS-29 change of patients and proxies. Receiver
operating characteristic (ROC) analyses were also performed to examine the diagnostic properties
of the MSIS-29 when completed by patients and proxies.
Results: 42 patients and proxy respondents completed the MSIS-29 at baseline and follow-up.
Patient-proxy differences between change scores on the physical and psychological MSIS-29
subscale were quite small, although large variability was found. The direction of mean change was
in concordance with the transition ratings of the patients. Results of the ROC analyses of the MSIS-
29 were similar when completed by patients (physical scale: AUC = 0.79, 95% CI: 0.65 – 0.93 and
0.66, 95% CI: 0.48 – 0.84 for the psychological scale) and proxies (physical scale: 0.80, 95% CI: 0.72
– 0.96 and 0.71, 95% CI: 0.56 – 0.87 for the psychological scale)
Conclusion: Although the results need to be further explored in larger samples, these results do
point towards possible use of proxy respondents to assess patient perceived treatment change at
the group level.
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Background
The clinical course of Multiple Sclerosis (MS) has a varia-
ble pattern and the impact on daily life of patients will
increase over time [1]. Treatment of MS is aimed at reduc-
ing this impact and to demonstrate this it is essential that
disease impact is measured in a reliable and valid way.
Due to the limited relation between 'objective' measures
like neurological examination and MRI and disease bur-
den as experienced by the patient, these measures are
questionable as main outcomes in rehabilitation and
therapeutic trials [2]. Recently and in line with this, there
is an increasing recognition and use of self-report meas-
urements in clinical settings, in order to capture the
patients' perspective. The incorporation of self-report
measurements in clinical research also has a downside;
there are several patient groups and situations in which
the ability to complete a questionnaire may be impaired.
Conditions such as cognitive impairment or mood distur-
bances, which also might play a role during the disease
course of MS [3-6], could lead to inaccurate self-report or
even loss of information due to missing data. This could
result in data which are not representative for the patient
population of interest. Exclusion of such patients, a some-
times chosen approach, may cause bias in the assessment
of health status. A possible solution for this problem is
use of proxy respondents (like the patients' partner) as an
alternative source of information [7]. They can provide
information on the health status of the patient that other-
wise would be inaccurate or even lost. In a previous cross-
sectional study we found that patient-proxy agreement
was good and proxy respondents might be of value in MS
research [8]. However, since factors such as cognitive
impairment and mood disturbances are not fixed, the
validity of measuring changes over time, which is a crucial
requirement for rehabilitation and trials, is especially vul-
nerable. Proxy respondents of MS patients should there-
fore also be able to assess change which is induced by
treatment. The objective of this study was therefore to
examine whether MS patients and proxy respondents




This study was performed at the MS Center of the VU
University Medical Center. MS patients, who visited the
center in order to receive intravenous steroid treatment
for worsening disease symptoms, were approached to
participate in the study. The inclusion criteria were that
the patient had to have a partner with whom they were
living together and this person had to be willing to par-
ticipate as a proxy respondent for the patient. The medi-
cal ethical committee of the VU University Medical
Center approved the study protocol and all participants
gave informed consent.
Measures and procedures
Assessment of patients and proxy respondents took place
before the start of the intravenous steroid treatment and
six to eight weeks after treatment. This follow-up period
was chosen, because this would most likely represent the
time in which change in disease status could be expected
[9]. Both patients and proxy respondents were asked to
complete the Multiple Sclerosis Impact Scale (MSIS-29),
at the initial visit at the MS Center and again at follow-up
when it was posted by mail.
The MSIS-29 measures disease impact of MS on daily life
and can be divided into two subscales; a physical scale
which consists of 20 items and a psychological scale
which consists of 9 items. Scores on the individual items
are added and transformed to a 0–100 scale, thereby gen-
erating two summary scores of both scales. Higher scores
indicated higher impact of MS on daily life [10]. The
proxy respondents completed a modified version of the
MSIS-29 in which all items were phrased in the third per-
son perspective. The proxy respondents were instructed to
assess the patient as the proxy respondent thought the
patient would rate himself or herself [11]. They had to
complete the MSIS-29 keeping in mind the following
question: 'How do you think the patient experiences the
impact of MS on his/her life?' The explicit instructions
were given that the proxy respondent had to complete the
questionnaires independently from the patient.
At follow-up, global ratings of the patient regarding their
extent of recovery from their recent deterioration were col-
lected. This was done by using a transition question,
which required the patient to compare their current health
status to their health status before treatment [12]. In this
study, patients were asked: 'In what way, do you believe,
is your situation regarding your MS recovered in compar-
ison to before the treatment?' Answer categories included
the following items: 'not at all' – 'a little' – 'moderately –
'quite a lot' – 'completely'. For analyses purposes these
items were later dichotomized into not improved ('not at
all' – 'a little') and improved ('moderately' – 'quite a lot' –
'completely'). The Expanded Disability Status Scale
(EDSS) and the MS subtype were available for all patients.
Data analyses
Two different approaches were used to analyse the data.
First, we focused on the absolute mean change scores on
the MSIS-29 of both patient and proxy respondents and
whether they agreed on the direction and the amount of
change. Therefore, the overall mean MSIS-29 scores and
overall mean change scores (follow-up minus baseline) of
the MSIS-29 were calculated for both scales. The mean
change scores were standardized by calculating effect sizes
(mean change/standard deviation of mean change) [13].
Independent t-tests were used to see whether the meanBMC Neurology 2009, 9:12 http://www.biomedcentral.com/1471-2377/9/12
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change scores of patients and proxy respondents differed
significantly from each other. Also, the correlation
between ratings of patients and proxy respondents was
calculated with the intraclass correlation coefficient
(ICC), which is the ratio of the variance between subjects
(variance of interest) and the total variance [14-16]. For
this study the two-way random model for absolute agree-
ment was used [17]. Standards for interpreting ICC values
are arbitrary but one can apply the standard reliability cri-
teria of an ICC > 0.70, which is adequate and an ICC >
0.80 is preferred [18].
In the second approach we focused on the transition rat-
ing of the patient. The transition rating was regarded as
the 'gold standard' and it was examined whether the
patient's judgement of change was reflected in the change
on the MSIS-29 of both patients and proxy respondents.
The patient sample was therefore divided into two groups;
the group in which the patients thought they had not
improved after treatment and the group in which the
patients thought they had improved after treatment. In
both groups, mean change scores were calculated for
patients and proxy respondents. Again, independent t-
tests were used to see whether the differences between
these change scores were significant. This time, respon-
siveness ratios were calculated. Responsiveness ratios
relate a clinically relevant change to the variability of the
change score in stable patients (mean change in improved
group/standard deviation of mean change in not
improved group) [19]. ICCs were also calculated. Scatter-
plots were made to visualize the distribution of individual
patient-proxy couples according to the transition ratings
and whether the changes on the MSIS-29 were in concord-
ance with the direction of the transition ratings.
The dichotomized transition ratings were also used in
receiver operating characteristic (ROC) analyses to see
whether the diagnostic properties of the MSIS-29 were
similar when completed by patients or proxy respondents.
Optimal cut-off points were also determined by means of
the ROC curve; the point most upper left in the curve rep-
resents the most optimal cut-off point under the assump-
tion that sensitivity to change is equally important to
specificity to change [20]. Using this optimal cut-off point
sensitivity and specificity values were determined. The
sensitivity of the MSIS-29 is the proportion of importantly
improved persons according to the transition rating, who
are correctly identified by the MSIS-29 as importantly
improved [21]. The specificity of the MSIS-29 is the pro-
portion of the persons who are not improved according to
the transition rating, who are correctly identified as not
improved by the MSIS-29 [21]. In addition, positive pre-
dictive values (PPV) and negative predictive values (NPV)
were calculated. The PPV is the proportion of patients
identified as improved by the MSIS-29 who are also
improved according to the transition rating. The negative
predictive value is the proportion of patients below the
cut-off of the MSIS-29 who were not improved according
to the transition score. Furthermore, the area under the
ROC curve (AUC) was calculated, which represents the
probability that the MSIS-29 correctly classified patients
as improved or unimproved [22]. The larger the value of
the AUC, the better the ability of the MSIS-29 to distin-




From October 2004 until October 2006, 55 patient-proxy
couples initially agreed to participate in the study. Missing
data was mainly caused by the fact that the MSIS-29 was
not returned at follow-up (nine patient-proxy couples),
despite telephone reminders. One patient and one proxy
respondent had more than 50% missing items on both
scales of the MSIS-29 and were therefore left out of the
analyses [23]; one patient withdrew from the study due to
worsening disease status and one patient-proxy couple
did not complete the MSIS-29 independently from each
other. Table 1 shows the characteristics of the remaining
42 patients and proxy respondents. Seven of these 42
patients already participated in an earlier published study
on longitudinal proxy measurements [24].
Table 2 displays the results of the comparison between the
absolute mean change scores on the MSIS-29 of patients
and proxy respondents. Both patients and proxy respond-
ents showed negative mean change scores on the physical
scale. This indicates a lower score on the MSIS-29 physical
scale after treatment, which subsequently pointed towards
an overall decrease in physical disease impact after treat-
ment. Patients also showed a decrease on the psychologi-
cal scale (-3.7 ± 15.2) but the proxy respondents remained
Table 1: Characteristics of patients and proxy respondents
Patients Proxy respondents
Total (n) 42 42
Female (n) 22 22
Age (years)* 45.7 (9.7) 47.7 (10.3)
Years since MS onset* 10.5 (6.1)




EDSS baseline ** 4.8 (2.5 – 8.0)
EDSS after treatment** 4.3 (1.0 – 8.0)
*Values are mean (SD)
** Values are median (range)
EDSS; Expanded Disability Status ScaleBMC Neurology 2009, 9:12 http://www.biomedcentral.com/1471-2377/9/12
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essentially unchanged (-0.1 ± 20.2). All mean values were
accompanied by large standard deviations, indicating
large variability on in the individual patient-proxy level.
Patients indicated a larger mean change on both scales in
disease impact in comparison to the proxy respondents,
which was reflected in the larger effect sizes. However,
independent t-test showed that these differences on both
scales were not significant (p = 0.05). ICCs were 0.58 for
the physical scale and 0.34 for the psychological scale,
indicating moderate to low agreement.
Table 3 shows the results of the analyses according to the
transition ratings. From the 42 patients, 25 patients indi-
cated that they had not improved after treatment and 17
patients indicated that they had improved after treatment.
The patients who considered themselves not improved
showed a very small decrease at group level for the physi-
cal scale (-0.2 ± 12.8) and no mean change at group level
on the psychological scale (0.0 ± 14.3). Yet, standard devi-
ations of the change scores were large.
Proxy respondents, on the other hand, indicated a small
increase in disease impact on both scales when the
patients indicated they did not improve: 4.0 ± 13.5 on the
physical scale and 6.9 ± 18.3 on the psychological scale.
Again, the variability was large. The differences between
patients and proxy respondents were not significant (p =
0.05). ICCs between patient and proxy scores were low for
both scales; 0.36 for the physical scale, 0.42 for the psy-
chological scale. The responsiveness ratio for the physical
scale was 1.29 and 0.64 for the psychological scale.
In the improved group, both patients and proxy respond-
ents showed large negative mean change scores, indicat-
ing less disease impact on the MSIS-29 after treatment.
Differences between the changes scores for patients and
proxy respondents appeared to be small, but standard
deviations were large. Hence, the differences were not sig-
nificant (p = 0.05). The ICC for the physical scale was
moderate (0.50) and extremely low for the psychological
scale (0.0). The responsiveness ratios were lower in the
improved group: 1.09 for the physical scale and 0.52 for
the psychological scale.
Figure 1 and 2 are scatterplots of the individual change
scores of the patient-proxy couples in the improved group
and the group who did not improve as defined by the
patient's reported transition question.
In figure 1, the individual change scores on the physical
scale of the improved group were predominantly (14
patient-proxy couples; 71%) located in the lower, left
quadrant which corresponded with negative change
scores on the MSIS-29. The individual change scores on
the physical scale of the not improved group were more
scattered among the four quadrants.







MSIS-29 physical scale baseline 48.8 ± 18.4 48.2 ± 18.0
MSIS-29 physical scale after treatment 42.0 ± 20.3 44.6 ± 20.8
Change on MSIS-29 physical scalea -6.8 ± 16.3 -3.6 ± 16.2
Effect size 0.4 0.2
Difference between change scoresb: -3.2 ± 14.8 (p = 0.367)
95% CI of the difference (-10.3 – 3.8)
ICC 0.58
MSIS-29 psychological scale baseline 31.4 ± 19.6 34.7 ± 20.4
MSIS-29 psychological scale after treatment 27.7 ± 17.8 34.6 ± 21.1
Change on MSIS-29 psychological scalea -3.7 ± 15.2 -0.1 ± 20.2
Effect size 0.2 0.0
Difference between change scoresb: -3.6 ± 20.5 (p = 0.353)
95% CI of the difference (-11.4 – 4.1)
ICC 0.34
a mean MSIS-29 scores after treatment minus mean MSIS-29 scores at baseline; negative values indicate improvement
b Patient mean change score minus proxy mean change score
CI = Confidence Interval ICC = Intraclass correlation coefficientBMC Neurology 2009, 9:12 http://www.biomedcentral.com/1471-2377/9/12
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In figure 2, the individual change scores on the psycholog-
ical scale of the improved group were also mostly located
in the lower left quadrant (10 patient-proxy couples;
58%). The individual change scores for the psychological
scale of the not improved group were also scattered
among the four quadrants.
Table 4 displays the results of the ROC analyses for
patients and proxy respondents. The most optimal cut-off
point for change on the physical scale, when completed
by patients, was -8.13. This value corresponded with a
sensitivity of 76% and a specificity of 76%. In case of a
change score of -8.13 or more on the physical scale of the
MSIS-29, 82% of the patients actually had changed (PPV).
In case of a change score below this point, 68% of the
patients actually had not changed (NPV). The cut-off
point for proxy respondents on the physical scale was -
6.88, which corresponded with a sensitivity of 80% and a
specificity of 71%. The positive predictive value in this
case was 80% and the negative predictive value was 71%.
The most optimal cut-off point for the psychological scale,
when completed by patients was -5.56, which corre-
sponded with a sensitivity of 72% and a specificity of
65%. In case of a change score of -5.56 or more, 74% of
the patients had changed. In case of a change score below
this point, 65% of the patients had not changed. The cut-
off point for proxy respondents, when they complete the
psychological scale, was -4.17. This cut-off point corre-
sponded with a sensitivity of 64% and a specificity of
71%. The positive predictive value in this case was 76%
and the negative predictive value was 57%.
ROC curves are presented in figure 3 and 4. The AUC val-
ues for the patients were 0.79 (95% CI: 0.65 – 0.93) for
the physical scale and 0.66 (95% CI: 0.48 – 0.84) for the
psychological scale. The same AUC values for the proxy
respondents were slightly larger at 0.80 (95% CI: 0.72 –
0.96) and 0.71 (95% CI: 0.56 – 0.87).
Discussion
The objective of this study was to examine whether proxy
respondents agreed with MS patients on treatment
induced change in disease impact. Ratings of treatment
induced change by proxy respondents may be useful for
patients with cognitive impairment or mood disorders or
other problems that would otherwise exclude them from
the study.
Table 3: Mean MSIS-29 scores and change scores for patients and proxies at baseline and after treatment according to the transition 
ratings
Not improveda (n = 25) Improvedb (n = 17)
MSIS-29 Patients Proxy respondents Patients Proxy respondents
Physical scale baseline 51.3 ± 16.5 51.0 ± 15.0 45.2 ± 20.9 44.2 ± 21.4
Physical scale after treatment 51.1 ± 16.8 55.0 ± 15.0 28.8 ± 17.7 29.5 ± 19.0
Change on MSIS-29 physical scalec -0.2 ± 12.8 4.0 ± 13.5 -16.4 ± 16.4 -14.7 ± 13.3
Responsiveness ratio 1.29 1.09
Difference between change scoresd: -4.2 ± 14.7 (p = 0.948) -1.8 ± 15.1 (p = 0.733)
95% CI of the difference (-11.7 – 3.3) (-12.2 – 8.6)
ICC 0.36 0.50
Psychological scale baseline 30.7 ± 19.1 33.2 ± 18.3 32.5 ± 20.9 36.9 ± 23.5
Psychological scale after treatment 30.7 ± 17.7 40.1 ± 22.3 23.4 ± 17.6 26.6 ± 16.8
Change on MSIS-29 psychological scalec 0.0 ± 14.3 6.9 ± 19.9 -9.1 ± 15.3 -10.3 ± 16.3
Responsiveness ratio 0.64 0.52
Difference between change scoresd: -6.9 ± 18.3 (p = 0.544) 1.1 ± 23.1 (p = 0.834)
95% CI of the difference (-16.7 – 3.0) (-8.9 – 12.2)
ICC 0.42 0.0
a combines the transition ratings 'not at all' – 'a little'
b combines the transition ratings 'moderately' – 'quite a lot' – 'completely'
c mean MSIS-29 scores after treatment minus mean MSIS-29 scores at baseline (negative values indicate improvement)
d patient mean change score minus proxy mean change score
CI = Confidence Interval
ICC = Intraclass correlation coefficientBMC Neurology 2009, 9:12 http://www.biomedcentral.com/1471-2377/9/12
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Data were analysed using two different approaches: the
first focussed on the comparison of the absolute mean
change scores on the MSIS-29 between patients and proxy
respondents; the second focussed on the transition ratings
as an external criterion to evaluate the change on the
MSIS-29. The latter approach was used to examine
whether repeated MSIS-29 assessment was capable of cap-
turing changes that were indicated by the patient them-
selves.
The first approach showed small differences between the
change scores indicating that there was acceptable agree-
ment between patients and proxy respondents on change
in disease impact after intravenous steroid treatment.
However, the variability on individual patient-proxy level
was large and ICCs were poor to moderate, indicating a
low level of agreement. However, since an ICC is based on
the variance of the sample, a lack of variance in change
scores could also have caused the low ICCs, rather than
lack of patient-proxy agreement [15]. Possibly, when
patients stayed stable, differences between the two meas-
urements could have been caused by measurement error
or random error, which could have lowered the calculated
ICCs.
Effect sizes suggested that the apparent treatment effect
was greater for patients in comparison to the proxy
respondents, but after division into the improved and not
improved group this difference diminished.
The second approach illustrated that less patients felt that
they had improved (40%) than not improved and patient-
proxy agreement in the improved group was better than in
the not improved group. There was a clear difference in
the amount of change between the not improved and
improved group, on both scales. This finding was under-
lined by the scatterplots and the responsiveness ratios; the
individual change scores for the patient-proxy couples in
the improved group were mainly located in the lower left
quadrant, which corresponded with less disease impact
after treatment. The individual changes in the not
improved group were more scattered around the quad-
rants. Responsiveness ratios were also larger in the
improved group when compared to the not improved
group. The ROC analyses showed similar sensitivity en
specificity values for both patients and proxy respondents.
Also, the values for the PPV and the NPV were similar and
the AUC was even slightly larger for proxy respondents on
both scales. These results indicated that the diagnostic
characteristics of the MSIS-29 were similar when com-
pleted by patients and proxy respondents. It is interesting
to note that a recently published study by Costelloe et al.
obtained similar values for the physical scale of the MSIS-
29 after performing an ROC analysis [25].
Several limitations should be taken into account when
interpreting these results. First of all, the attrition rate was
high, mainly caused by the fact that the MSIS-29 was not
returned at follow-up. This could have caused selection
bias. The final results in this study are based on a small
sample size of 42 patients. Therefore, current findings
should be interpreted with caution. Larger samples will
Individual change scores for patients and proxy respondents  on the physical scale Figure 1
Individual change scores for patients and proxy 
respondents on the physical scale.
Individual change scores for patients and proxy respondents  on the psychological scale Figure 2
Individual change scores for patients and proxy 
respondents on the psychological scale.BMC Neurology 2009, 9:12 http://www.biomedcentral.com/1471-2377/9/12
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provide the opportunity to create more subgroups based
on, for example, disability of the patient. Also, given the
small sample sizes, there might not have been enough
power to detect a true difference in scores in the sub-
groups (not improved, improved). There was no data col-
lected on cognitive status or mood disturbances in this
sample and we can therefore not make any assumptions
on whether these factors might have influenced the
results. There has been criticism on the use of transition
ratings which could introduce methodological problems
[26]. There is evidence that patients have difficulty with
recalling prior health status and their judgement is there-
fore based on their present state, rather than on change in
health status [27]. It should be noted that the answer cat-
egories of the transition question did not have the option
to indicate that the patient felt worse if this should be the
case. This could give more insight into the patients who
indicated that they did not change at all.
Conclusion
This is the first study to explore patient-proxy agreement
in an intervention setting in MS research. Despite its lim-
itations and although the results need to be further
explored in larger samples, these results point towards
possible use of proxy respondents to assess patient per-
ceived treatment change at the group level.
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